Literature DB >> 30170976

Improved survival with adjuvant brachytherapy in stage IA endometrial cancer of unfavorable histology.

Ashwin Shinde1, Richard Li1, Arya Amini1, Yi-Jen Chen1, Mihaela Cristea2, Thanh Dellinger3, Wenge Wang2, Mark Wakabayashi3, Sushil Beriwal4, Scott Glaser5.   

Abstract

PURPOSE: We evaluated the utilization of vaginal brachytherapy (BT) and the resulting impact on survival in stage IA endometrial cancer of clear cell (CC), papillary serous (PS), and carcinosarcoma (CS) histology.
METHODS: Patients with uterine cancer diagnosed from 2004 to 2015 were identified from the National Cancer Database. Patients underwent hysterectomy, showing FIGO stage IA disease with CC, PS, or CS histology. Logistic regression was used to evaluate predictors of BT utilization and to generate propensity scores. Survival was compared using log-rank test and Cox proportional hazards modeling, with propensity score adjustment.
RESULTS: We identified 5711 patients who underwent hysterectomy showing FIGO pT1a, N0 or NX endometrial cancer with CC, PS, or CS histology, of which 29.5% received BT. Multivariate predictors of increased receipt of BT were identified. With a median follow-up of 3.3 years, 3-year overall survival (OS) was 87% for those receiving BT versus 78% for those without (p < 0.001). A survival benefit to BT was maintained across histologies. Similar results were seen whether tumor was confined to endometrium or had <50% myometrial invasion. On multivariate analysis, receipt of BT was associated with increased survival (hazard ratio [HR] 0.75, 95% confidence interval 0.65-0.87, p < 0.001). The benefit of BT persisted after propensity score adjustment (HR 0.76, p < 0.001).
CONCLUSIONS: In this cohort of women with stage IA endometrial cancer of unfavorable histology, the use of BT was associated with improved survival. In this study, 29.5% of patients in our cohort received BT.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Brachytherapy; Carcinosarcoma; Chemotherapy; Clear cell; Endometrial cancer; Papillary serous

Mesh:

Year:  2018        PMID: 30170976     DOI: 10.1016/j.ygyno.2018.08.028

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  5 in total

1.  ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma.

Authors:  Nicole Concin; Carien L Creutzberg; Ignace Vergote; David Cibula; Mansoor Raza Mirza; Simone Marnitz; Jonathan A Ledermann; Tjalling Bosse; Cyrus Chargari; Anna Fagotti; Christina Fotopoulou; Antonio González-Martín; Sigurd F Lax; Domenica Lorusso; Christian Marth; Philippe Morice; Remi A Nout; Dearbhaile E O'Donnell; Denis Querleu; Maria Rosaria Raspollini; Jalid Sehouli; Alina E Sturdza; Alexandra Taylor; Anneke M Westermann; Pauline Wimberger; Nicoletta Colombo; François Planchamp; Xavier Matias-Guiu
Journal:  Virchows Arch       Date:  2021-02       Impact factor: 4.064

Review 2.  Controversies in the Management of Early-stage Serous Endometrial Cancer.

Authors:  Alyssa Larish; Andrea Mariani; Carrie Langstraat
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

3.  Exosomal transfer of tumor-associated macrophage-derived hsa_circ_0001610 reduces radiosensitivity in endometrial cancer.

Authors:  Xiaobin Gu; Yonggang Shi; Meilian Dong; Li Jiang; Jing Yang; Zheyan Liu
Journal:  Cell Death Dis       Date:  2021-08-30       Impact factor: 8.469

Review 4.  Uterine carcinosarcoma vs endometrial serous and clear cell carcinoma: A systematic review and meta-analysis of survival.

Authors:  Antonio Raffone; Antonio Travaglino; Diego Raimondo; Manuela Maletta; Valentino De Vivo; Umberto Visiello; Paolo Casadio; Renato Seracchioli; Fulvio Zullo; Luigi Insabato; Antonio Mollo
Journal:  Int J Gynaecol Obstet       Date:  2021-12-11       Impact factor: 4.447

5.  Therapeutic Challenges in Patients with Gynecologic Carcinosarcomas: Analysis of a Multicenter National Cohort Study from the French Prospective TMRG Network.

Authors:  Clémence Romeo; Olivia Le Saux; Margaux Jacobs; Florence Joly; Gwenael Ferron; Laure Favier; Jean-David Fumet; Nicolas Isambert; Pierre-Emmanuel Colombo; Renaud Sabatier; Ludovic Bastide; Amandine Charreton; Mojgan Devouassoux-Shisheboran; Witold Gertych; Coraline Dubot; Diana Bello Roufai; Guillaume Bataillon; Dominique Berton; Elsa Kalbacher; Patricia Pautier; Christophe Pomel; Caroline Cornou; Isabelle Treilleux; Audrey Lardy-Cleaud; Isabelle Ray-Coquard
Journal:  Cancers (Basel)       Date:  2022-01-12       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.